Clinical pharmacology

Molecular Templates Strengthens Board of Directors and Management Team

Retrieved on: 
Wednesday, March 2, 2022
Associate, Industry, Clinical pharmacology, Corporation, ETB (company), Regulatory science, Lawyer, Biology, Board, COVID-19, Medicine, CSO, Partnership, Nasdaq, Hematology, Private Securities Litigation Reform Act, Blank Rome, Forward-looking statement, General counsel, Rutgers School of Management and Labor Relations, Pfizer, Gruia, Company, SEC, CEO, Rutgers Law School, Rutgers Journal of Law & Public Policy, Regulatory affairs, Neoplasm, IND, Pharmacia, Boston University, Novartis, Coley's toxins, Patient, The arts, Immunotherapy, Mammography, Safety, Society of American Business Editors and Writers, Board of directors, Paris Descartes University, Cancer, Public policy, René, ETB, Sanofi, GLOBE, Therapy, Pharmaceutical industry, Management, Law, Director, Molecule, Biostatistics, Toxicology, History

AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel.

Key Points: 
  • Dr. Gruia brings a wealth of industry knowledge to our Board of Directors, said Barry Selick, Ph.D., Chairman of the Board of Molecular Templates.
  • Dr. Gruia stated, I am pleased to have the opportunity to join the Molecular Templates Board of Directors.
  • Megan Filoon joined Molecular Templates in May 2018 as Corporate Counsel and most recently served as Vice President, Legal.
  • Megans diverse and extensive legal expertise and her track record of success make her a great addition to the MTEM senior management team, said Eric Poma, CEO and CSO of Molecular Templates.

Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors

Retrieved on: 
Thursday, February 24, 2022
Failure, Security (finance), Company, Senior advisor, Compugen, Senior, Clinical pharmacology, R, Nasdaq, Private Securities Litigation Reform Act, Research, Bispecific monoclonal antibody, Board of directors, McKinsey & Company, Retirement, Risk, Board, Biochemistry, Novartis, TIGIT, Drug development, IO, Pharmacology, U.S. Securities and Exchange Commission, Bristol Myers Squibb, Terminology, Pharmaceutical Research and Manufacturers of America, University of Nijmegen (1655–80), TEL, AstraZeneca, D, Pharmacometrics, Atomic Energy Regulatory Board, Compugen (Israeli company), PDUFA, Forward-looking statement, Patient, Immunotherapy, University, Annual report, Industry, Science and technology in Asia, Acquisition, FDA, SEC, Pharmaceutical industry, Safety, PVRIG, Bayer, Biology

In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.

Key Points: 
  • In addition, the Company announced that Dr. Jean-Pierre Bizzari will retire from its Board of Directors.
  • "I am delighted to welcome Math to Compugen's Board," said Paul Sekhri, Chairman of the Board.
  • I would also like to thank Jean-Pierre who will end his tenure as a director on March 1, 2022, for his contributions to Compugen."
  • "I had the privileged opportunity to play a key role in the introduction of transformational immune-based therapies that are today changing patients' lives.

CenExel Clinical Research Acquires CTSdatabase

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Risk, Therapy, Partnership, Record, Lake City, Board, Contract research organization, Privacy, Cros, Clinical trial, Safety, Acquisition, Clinical and Vaccine Immunology, Clinical pharmacology, Patient, Principal investigator, CRO, History, Goal, Central nervous system, CNS, Health, Time, Pharmaceutical industry, Medical device, Neurology, Dermatology, Pain, Psychiatry

Salt Lake City, Utah, Feb. 22, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of CTSdatabase, a cutting edge and global duplicate subject detection service.

Key Points: 
  • Salt Lake City, Utah, Feb. 22, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of CTSdatabase, a cutting edge and global duplicate subject detection service.
  • CTSdatabase will also continue to function independently from CenExel, benefiting from shared resources while supporting sites, trials, and exclusive sponsor and Contract Research Organization (CRO) partnerships outside of CenExel.
  • CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has enthusiastically pursued both organic growth and acquisitions of state-of-the-art research centers around the U.S.
  • CenExel Clinical Research ( www.CenExel.com ) provides unparalleled medical and scientific support in the design and execution of clinical trials.

VaxCorps to Expand Vaccine Site Network in 2022

Retrieved on: 
Monday, February 14, 2022
Manna, Benchmark, Centricity, Patient, CEO, CMV, HSV, Achievement, Escherichia coli, Smallpox, Congress, III, Goal, Safety, Globe, Clinical pharmacology, Clinical trial, Research, AVA, COVID-19, HBV, Industry, Pharmaceutical industry, Pain, Neurology, Dermatology, Psychiatry

With this expansive addition to the network, VaxCorps continues to grow its geographic access to diverse patient populations.

Key Points: 
  • With this expansive addition to the network, VaxCorps continues to grow its geographic access to diverse patient populations.
  • VaxCorps, who is a silver sponsor for this year's World Vaccine Congress, has achieved a dignified title of having the most ViE wins for a clinical research network.
  • Additionally, the VaxCorps global network was the first to have at least one company participate in over 97% of all vaccine trials during that period.
  • This is an exciting achievement to have going into World Vaccine Congress 2022 and we hope to earn your vote as Best Clinical Trial Network. "

CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center

Retrieved on: 
Tuesday, January 11, 2022
SOP, Research, Patient, Valuation, Clinical trial, Record, CNS, Principal investigator, Lubal Manufacturing & Distributing Company, Movement disorders, Partnership, Corporate services, Investment, GLOBE, Solution, Health, Health care, Movement, Clinical and Vaccine Immunology, Goal, Essential tremor, Consumer, Therapy, Technology, Contract, Lake City, Principal, Clinical pharmacology, List of life sciences, Acquisition, Pharmaceutical industry, Financial services, Pain, Neurology, Psychiatry, Dermatology

Salt Lake City, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of Rocky Mountain Movement Disorders Centers clinical research site operations.

Key Points: 
  • Salt Lake City, Utah, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of Rocky Mountain Movement Disorders Centers clinical research site operations.
  • CenExel Rocky Mountain Clinical Research (CenExel RMCR) is a leading movement disorders-focused research facility in Denver, with experience spanning more than 100 clinical trial studies.
  • CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has enthusiastically pursued both organic growth and acquisitions of state-of-the-art research centers around the U.S.
  • CenExel Clinical Research ( www.CenExel.com ) provides unparalleled medical and scientific support in the design and execution of clinical trials.

CenExel Clinical Research Acquires California Neuroscience Research

Retrieved on: 
Monday, January 10, 2022
Ri Hong-sop, Research, Patient, Central nervous system, Clinical trial, Record, CNS, Principal investigator, Anxiety, Ethics, Safety, GLOBE, Health, Leadership, History, Clinical and Vaccine Immunology, Goal, Therapy, Contract, Lake City, Principal, CNR, Clinical pharmacology, Partnership, Acquisition, Pharmaceutical industry, Pain, Neurology, Psychiatry, Migraine, Depression, Dermatology

Salt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of California Neuroscience Research (CenExel CNR), a clinical research facility in Los Angeles with two decades of experience in neurological and psychiatric studies.

Key Points: 
  • Salt Lake City, Utah, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of California Neuroscience Research (CenExel CNR), a clinical research facility in Los Angeles with two decades of experience in neurological and psychiatric studies.
  • CenExel CNR is an ideal fit for the CenExel network and our emphasis on CNS clinical research, said Tom Wardle, CenExel CEO.
  • CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has enthusiastically pursued both organic growth and acquisitions of state-of-the-art research centers around the U.S.
  • CenExel Clinical Research ( www.CenExel.com ) provides unparalleled medical and scientific support in the design and execution of clinical trials.

HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology

Retrieved on: 
Thursday, January 6, 2022
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, NASH, Therapy, University, Fatty liver disease, Chronic liver disease, Roy Taylor (scientist), Lists of diseases, Patient, Primary biliary cholangitis, IND, T2DM, Chen Jin, Pharmacology, Buffalo, NAFLD, PSC, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Degenerative disease, SVP, Institute of Liver and Biliary Sciences, Drug, Clinical pharmacology, Amgen, State, Primary sclerosing cholangitis, HighTide, State university system, PBC, NDA, Pharmaceutical industry, Novartis

HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.

Key Points: 
  • HighTide Therapeutics Inc., a clinical-stage biopharmaceutical company developing treatments for liver diseases, gastrointestinal diseases and metabolic disorders, today announced the appointment of Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology.
  • Dr. Chen has over 16 years of experience in clinical pharmacology & clinical development.
  • Most recently Dr. Chen served as Clinical Development Director at Novartis where she contributed to the development of therapeutics for cardio, renal, metabolic, and liver diseases.
  • We are very pleased to welcome Jin to the HighTide team, said Liping Liu, Ph.D., Chief Executive Officer of HighTide.

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

Retrieved on: 
Monday, December 13, 2021
Waiha, Method, Forward-looking statement, Poster, Pharmacology, Safety, Securities Exchange Act of 1934, Drug Quality and Security Act, Cold agglutinin disease, RBC, Brain, Private Securities Litigation Reform Act, Nasdaq, Complement component 1q, Clinician Administered PTSD Scale, CAD, COVID-19, Time-invariant system, Securities Act of 1933, Autoantibody, SEC, C4, Serum, Probability, Patient, Autoimmune hemolytic anemia, Society, Terminology, Neurodegeneration, Red blood cell, Eye, GLOBE, AIHA, FRCP, Blood, ASH, MBBS, Technology, Clinical pharmacology, Pharmaceutical industry, Vaccine

In addition, Annexon reported preclinical data supporting the role of the complement pathway in warm autoimmune hemolytic anemia (wAIHA).

Key Points: 
  • In addition, Annexon reported preclinical data supporting the role of the complement pathway in warm autoimmune hemolytic anemia (wAIHA).
  • The data were presented during two poster sessions at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition.
  • ANX009 was shown to be well-tolerated with complete and sustained C1q inhibition, supporting its continued clinical advancement.
  • Data reported in the poster are from a single and multiple ascending dose Phase 1 trial of ANX009 in 48 healthy volunteers.

CenExel Clinical Research Acquires Advanced Memory Research Institute

Retrieved on: 
Thursday, August 19, 2021
Dementia, Record, SOP, CNS, Center, Growth, Therapy, Strategic planning, Acquisition, GLOBE, Principal investigator, Provident, Knowledge, Amnesia, Contract, Vaccine, Lake City, Clinical pharmacology, Health, Goal, Patient, Solution, LinkedIn, Principal, AMRI, MD, Pharmaceutical industry

Salt Lake City, Utah, Aug. 19, 2021 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of Advanced Memory Research Institute (CenExel AMRI), the largest Alzheimers Disease clinical research site in the Northeast.

Key Points: 
  • Salt Lake City, Utah, Aug. 19, 2021 (GLOBE NEWSWIRE) -- CenExel Clinical Research, Inc., ( CenExel ) announces the acquisition of Advanced Memory Research Institute (CenExel AMRI), the largest Alzheimers Disease clinical research site in the Northeast.
  • CenExel AMRI conducts Phase I through Phase IV studies, primarily in Alzheimers Disease, Memory Loss, and Dementia research.
  • CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has enthusiastically pursued both organic growth and acquisitions of state-of-the-art research centers around the U.S.
  • CenExel Clinical Research ( www.CenExel.com ) provides unparalleled medical and scientific support in the design and execution of clinical trials.

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Life sciences, Natural sciences, Pharmaceutical industry, Drug discovery, Clinical research, Food and Drug Administration, Clinical pharmacology, Clinical trial, Pharmacology, Drug development, ADME

Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.

Key Points: 
  • Having successfully completed our IND-enabling studies and Investigational Brochure we have taken a large step closer to launching human clinical trials for a potential treatment for this unmet medical need, commented Jacob VanLandingham, Executive VP of Drug Development of Odyssey Group International.
  • The IB includes the pre-clinical safety and efficacy data, the design for Phase 1 clinical trials and the informed consent to enroll subjects in the trial.
  • These study areas include the following: Safety Pharmacology, Toxicology, CMC (Chemistry Manufacturing and Control) activities, ADME (Absorption, Distribution, Metabolism and Excretion) and Genotoxicity.
  • said Michael Redmond, CEO of Odyssey Group International
    Odyssey Group International, Inc. (OTC: ODYY ) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.